Katie Peng Joins Adicet Bio's Board of Directors, Bringing Extensive Biotech Experience

Adicet Bio, Inc., a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer, has announced the appointment of Katie Peng to its Board of Directors. Peng, who currently serves as the Chief Commercial Officer at Denali Therapeutics Inc., brings a wealth of industry and commercial expertise to the company.

With a successful track record in the biotech industry, Peng has extensive experience in leading global commercialization efforts and managing portfolios of multiple products. She has played a crucial role in launching successful therapies, including OCREVUS for multiple sclerosis, Evrysdi for spinal muscular atrophy (SMA), and HEMLIBRA for hemophilia A. Her expertise spans marketing, sales, market access, medical affairs, and business planning.

Adicet Bio is dedicated to developing innovative treatments using allogeneic gamma delta T cell therapies for various types of cancer. Their pipeline includes ADI-001, which is being advanced for the treatment of hematologic and solid tumors. With Peng's appointment, Adicet Bio aims to leverage her extensive industry knowledge and commercial experience to accelerate the development and potential commercialization of ADI-001 and other future therapies.

Commenting on her appointment, Peng expressed her excitement to join Adicet Bio's Board of Directors during this pivotal time for the company. She highlighted the potential of ADI-001 in post CAR T large B-cell lymphoma and emphasized her commitment to working collaboratively with the board and management to drive the company's success.

Chen Schor, President, and Chief Executive Officer of Adicet Bio expressed his delight in welcoming Peng to the board, citing her proven success as a commercial leader in the biotech industry. He emphasized that Peng's expertise and strategic insights will be invaluable as the company advances its pipeline of allogeneic gamma delta T cell therapy candidates.

Peng's appointment reflects Adicet Bio's commitment to assembling a board with diverse perspectives and extensive industry experience. The company aims to leverage this expertise to enhance its research, development, and commercialization efforts. With a focus on advancing innovative cancer therapies, Adicet Bio is poised to make significant contributions to the field of biotechnology under Peng's guidance and the collective expertise of its Board of Directors.